MedTrace Logo

An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

NCT07705568 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-07-16

No results posted yet for this study

Summary

The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2) to assess efficacy of multiple doses of PST-611 by assessing retinal morphology and visual function changes over time.

Participants will:

* receive one dose every 20 weeks, for a total of 3 doses.
* will be followed up for a total of 52 weeks following the first PST-611 dose.

Conditions

Interventions

BIOLOGICAL

PST-611

PST-611 is a naked plasmid DNA encoding human transferrin administered into the ciliary muscle

Sponsors & Collaborators

  • Eyevensys

    lead INDUSTRY

Principal Investigators

  • Karine Bigot, PhD · PulseSight Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07705568 on ClinicalTrials.gov